Skip to main content
Research

Publications: Mrs Rhiannon Roberts

Zardab M, Balarajah V, Banerjee A, Stasinos K, Saad A, Imrali A, Hughes C, Roberts R et al. ( 2022 ) . Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospective Case-Control Study . Cancers vol. 15 , ( 1 )
Debernardi S, O’Brien H, Algahmdi AS, Malats N, Stewart GD, PljeĊĦa-Ercegovac M, Costello E, Greenhalf W et al. ( 2020 ) . A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study . PLOS Medicine vol. 17 , ( 12 )
Kocher HM, Basu B, Froeling FE, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al. ( 2020 ) . STARPAC clinical trial . Pancreatology vol. 20 , ( 8 )
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al. ( 2020 ) . Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer . Nature Communications vol. 11 , ( 1 )
Schilling K, Larner F, Saad A, Roberts R, Kocher HM, Blyuss O, Halliday AN, Crnogorac-Jurcevic T ( 2020 ) . Urine metallomics signature as an indicator of pancreatic cancer . Metallomics: integrated biometal science
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al. ( 2019 ) . 700P STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer . Annals of Oncology vol. 30 ,
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al. ( 2019 ) . STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer . ANNALS OF ONCOLOGY . vol. 30 ,